<sup>19</sup>
            F magnetic resonance imaging for stem/progenitor cell tracking with multiple unique perfluorocarbon nanobeacons

Partlow, Kathryn C.; Chen, Junjie; Brant, Jason A.; Neubauer, Anne M.; Meyerrose, Todd E.; Creer, Michael H.; Nolta, Jan A.; Caruthers, Shelton D.; Lanza, Gregory M.; Wickline, Samuel A.

doi:10.1096/fj.06-6505com

Cited by 290 publications

(297 citation statements)

References 35 publications

Supporting

Mentioning

284

Contrasting

Order By: Relevance

“…It has already been demonstrated that bSSFP is the most SNR efficient pulse sequence in use. 30 Proof of principle that bSSFP was advantageous for the detection of 19 F-labeled stem cells has been previously reported by Partlow et al 31 In this paper, a liquid PFC was developed and used to label stem/ progenitor cells in culture. A single mouse then received an IM injection of 4 million fixed PFC-labeled cells and was imaged after euthanasia at 1.5 T with 2D bSSFP.…”

Section: Cell Detection With Bssfpmentioning

confidence: 76%

See 1 more Smart Citation

In vivo MR detection of fluorine-labeled human MSC using the bSSFP sequence

Ribot¹,

Gaudet²,

Chen³

et al. 2014

IJN

View full text Add to dashboard Cite

Mesenchymal stem cells (MSC) are used to restore deteriorated cell environments. There is a need to specifically track these cells following transplantation in order to evaluate different methods of implantation, to follow their migration within the body, and to quantify their accumulation at the target. Cellular magnetic resonance imaging (MRI) using fluorine-based nanoemulsions is a great means to detect these transplanted cells in vivo because of the high specificity for fluorine detection and the capability for precise quantification. This technique, however, has low sensitivity, necessitating improvement in MR sequences. To counteract this issue, the balanced steady-state free precession (bSSFP) imaging sequence can be of great interest due to the high signal-to-noise ratio (SNR). Furthermore, it can be applied to obtain 3D images within short acquisition times. In this paper, bSSFP provided accurate quantification of samples of the perfluorocarbon Cell Sense-labeled cells in vitro. Cell Sense was internalized by human MSC (hMSC) without adverse alterations in cell viability or differentiation into adipocytes/osteocytes. The bSSFP sequence was applied in vivo to track and quantify the signals from both Cell Sense-labeled and iron-labeled hMSC after intramuscular implantation. The fluorine signal was observed to decrease faster and more significantly than the volume of iron-associated voids, which points to the advantage of quantifying the fluorine signal and the complexity of quantifying signal loss due to iron.

show abstract

Section: Cell Detection With Bssfpmentioning

confidence: 76%

“…For example, Partlow et al injected and detected 4 million cells in 50 µL at 1.5 T ex vivo. 31 The voxel size was 2.5×2.5×35 mm (∼220 µL); therefore, they detected 4 million cells in a voxel. They did this in a far shorter imaging time of 7 minutes compared to our 40 minutes.…”

Section: Cell Detection With Bssfpmentioning

confidence: 99%

In vivo MR detection of fluorine-labeled human MSC using the bSSFP sequence

Ribot¹,

Gaudet²,

Chen³

et al. 2014

IJN

View full text Add to dashboard Cite

show abstract

“…[84][85][86] Additionally, in vivo perfluorocarbon emulsion infusion followed by 19 F MRI has been shown to preferentially detect areas of inflammation both in the CNS and systemically via preferential uptake by CD68+ macrophages, providing a non-invasive measure of disease activity in murine models of inflammatory disease. [87][88][89][90] Thus, the advantage of these labelling modalities includes the ability to directly visualise (and potentially in an EAE mouse model in which human MSCs engineered to express a myelin oligodendrocyte glycoprotein-specific receptor were intranasally delivered and found to significantly improve EAE symptoms better than non-engineered human MSCs, and prevented further EAE induction.…”

Section: Dmd = Disease-modifying Drug; Ipsc = Induced Pluripotent Stementioning

confidence: 99%

Cell-Based Therapeutic Strategies in Multiple Sclerosis

Rossman

Cohen²

2014

European Neurological Review

View full text Add to dashboard Cite

Multiple sclerosis (MS) is an immune-mediated disease in which acute inflammatory demyelination leads to axonal injury and neurodegeneration, and is manifested clinically by relapsing-remitting neurological deficits superimposed on chronic accumulation of disability. MS treatments are largely immunomodulatory with little, if any, effect on neurodegeneration. Mesenchymal stem cells (MSCs) are pluripotent cells derived from adult tissues with intrinsic anti-inflammatory and repair-promoting properties. They cross the blood-brain barrier and target perivascular spaces, which are the sites of inflammatory cell infiltration in MS. In vitro, MSCs can be purified and expanded, labelled for post-transplant tracking and be manipulated to express surface receptors or neurotrophic factors for central nervous system (CNS) targeting or neuroprotection, respectively. Animal models of MS, traumatic CNS injury and neurodegenerative diseases demonstrate clinical and pathological benefits following MSC transplantation. Potentially, MSCs can be used to treat MS patients at various disease stages, which is the current focus of ongoing phase I/II clinical trials at multiple centres. KeywordsMultiple sclerosis, mesenchymal stem cell, clinical trial, induced pluripotent stem cell, experimental autoimmune encephalitis exposure and smoking, and these likely interact heterogeneously with genetic factors across the MS population. 5,6 Thus, the natural history of MS varies between patients. The average age of onset is typically in the third decade and there is a peak prevalence in the fifth decade of life. Paediatric MS is rarer, particularly in patients aged younger than 9 years of age, though there is a growing recognition of early-onset MS and its implications for earlier disability than adult-onset MS. 4,7,8 The prevalence of MS has been estimated at one to two per 1,000 in North America and northern Europe, but the incidence and prevalence vary geographically, seem to increase with latitude and appear to be increasing, particularly in women.9 A systematic review of the financial burden of MS in the US found a range of $8,528-54,244 per patient per year, with approximately 77 % representing direct costs to the patient (i.e. prescription medications), making MS the second most costly disease in the US behind congestive heart failure. Current Treatments in Relapsing-Remitting Multiple SclerosisThe mainstay of MS therapy has been anti-inflammatory diseasemodifying drugs (DMDs) that target various immune system pathways to decrease or prevent the continuation of an immune-mediated destructive process. 4 In the clinical context, the goal of therapy is twofold: 1) minimising accumulated disability associated with clinical relapses; and 2) preventing the MRI lesion activity, which can occur in the absence of clinical symptoms. The mechanisms of action, route of delivery, safety, tolerability and side-effect profiles differ between DMDs, though they all serve these two principles. Thus, DMD treatment should be considered early follow...

show abstract

“…MRI and magnetic resonance spectroscopy are common imaging modalities for in vivo stem cell tracking in both preclinical and clinical settings (Hoehn, Kustermann et al 2002;Modo, Cash et al 2002;van den Bos, Wagner et al 2003;Kustermann, Roell et al 2005;Crowder, Brant et al 2006;Jansen, Shamblott et al 2006;Au, Lam et al 2007;Hsiao, Tai et al 2007;Magnitsky, Walton et al 2007;Partlow, Chen et al 2007;Politi, Bacigaluppi et al 2007;Suzuki, Cunningham et al 2007;Dash, Chan et al 2008;Himmelreich and Hoehn 2008;Kim and Song 2008;Terrovitis, Stuber et al 2008;Wu, Hu et al 2008;Kedzioreik, Ouwerkerk et al 2009;Kim, Huh et al 2009;Lythgoe 2009;Reekmans, Tambuyzer et al 2009;Solanky, Chung et al 2010;Tseng, Shih et al 2010;Chien, Hsiao et al 2011). Extraordinary three dimensional and anatomic resolution and high safety profile are the main advantages.…”

Section: Mrimentioning

confidence: 99%